Target Name: CD70
NCBI ID: G970
Other Name(s): TNFSF7 | Tumor necrosis factor ligand 8A | Ki-24 antigen | surface antigen CD70 | CD70 antigen (isoform 1) | CD27LG | CD27 ligand | LPFS3 | CD70 molecule | CD70 variant 1 | Surface antigen CD70 | Tumor necrosis factor ligand superfamily member 7 | CD27L | CD70 antigen | tumor necrosis factor ligand superfamily member 7 | CD70 molecule, transcript variant 1 | CD70 antigen (isoform 2) | TNLG8A | CD70_HUMAN | CD27-L | tumor necrosis factor ligand 8A | CD70 molecule, transcript variant 2 | Tumor necrosis factor (ligand) superfamily, member 7 | CD70 variant 2

CD70 as a Potential Drug Target and Biomarker for the Treatment of Chronic Obstructive Pulmonary Disease

Abstract:

Chronic Obstructive Pulmonary Disease (COPD) is a leading cause of morbidity and mortality worldwide, with an estimated 17 million people diagnosed in the United States alone. The persistent airflow obstruction and inflammation associated with COPD can lead to a range of severe consequences, including lung fibrosis, chronic hypoxia, and decreased quality of life. CD70, a protein that is expressed in the airways of individuals with COPD, has been identified as a potential drug target and biomarker for the treatment of COPD. This article will review the current literature on CD70 and its potential as a drug target and biomarker for the treatment of COPD.

Introduction:

COPD is a progressive lung disease that is characterized by persistent airflow obstruction and inflammation. The airways of individuals with COPD are filled with mucus, which hinders airflow and leads to chronic hypoxia, which can worsen symptoms and increase the risk of complications. The underlying causes of COPD are not fully understood, but research has identified several key factors that contribute to its development, including genetic and environmental factors.

CD70:

CD70 is a protein that is expressed in the airways of individuals with COPD. It is a member of the T-cell antigen 70 (TCA70) family and is involved in the immune response to airway infection. CD70 is also a potent chemoattractant for neutrophils, which are a key component of the immune response to airway infection.

CD70 has been shown to be involved in several processes that are associated with COPD, including inflammation, fibrosis, and hypoxia. For example, studies have shown that CD70 is involved in the recruitment of neutrophils to the airways of individuals with COPD, which contributes to inflammation and tissue damage. Additionally, CD70 has been shown to promote the production of extracellular matrix (ECM) components, such as collagen, in fibroblasts, which are involved in the development of fibrosis.

CD70 as a drug target:

CD70 has potential as a drug target for the treatment of COPD because of its involvement in several processes that are associated with this disease. One potential mechanism by which CD70 could be targeted is by inhibiting its ability to recruit neutrophils to the airways. This could be done by inhibiting the chemotactic activity of CD70 or by blocking its ability to interact with neutrophils. In addition, CD70 may be a good candidate for a COPD drug because it has been shown to be involved in several processes that contribute to the development of fibrosis, including the production of ECM components and the regulation of cell proliferation.

CD70 as a biomarker:

CD70 has also been identified as a potential biomarker for the treatment of COPD. The production of ECM components, such as collagen, by CD70-positive fibroblasts may be an indicator of the severity of COPD and could be used as a biomarker for this disease. In addition, the number of neutrophils recruited to the airways by CD70 may be an indicator of the level of inflammation in the airways, which is a key predictor of COPD severity.

Conclusion:

CD70 is a protein that is expressed in the airways of individuals with COPD and has been shown to be involved in several processes that are associated with this disease. As a potential drug target and biomarker for the treatment of COPD, CD70 is a promising target for the development of new treatments for this progressive lung disease. Further research is needed to fully understand its potential and to develop safe and effective treatments for COPD.

Protein Name: CD70 Molecule

Functions: Cytokine which is the ligand for CD27. The CD70-CD27 pathway plays an important role in the generation and maintenance of T cell immunity, in particular during antiviral responses. Upon CD27 binding, induces the proliferation of costimulated T-cells and enhances the generation of cytolytic T-cells

More Common Targets

CD72 | CD74 | CD79A | CD79B | CD8 | CD80 | CD81 | CD81-AS1 | CD82 | CD83 | CD84 | CD86 | CD8A | CD8B | CD8B2 | CD9 | CD93 | CD96 | CD99 | CD99L2 | CD99P1 | CDA | CDADC1 | CDAN1 | CDC123 | CDC14A | CDC14B | CDC14C | CDC16 | CDC20 | CDC20-DT | CDC20B | CDC20P1 | CDC23 | CDC25A | CDC25B | CDC25C | CDC26 | CDC27 | CDC27P2 | CDC34 | CDC37 | CDC37L1 | CDC37P1 | CDC40 | CDC42 | CDC42BPA | CDC42BPB | CDC42BPG | CDC42EP1 | CDC42EP2 | CDC42EP3 | CDC42EP4 | CDC42EP5 | CDC42SE1 | CDC42SE2 | CDC45 | CDC5L | CDC5L complex | CDC6 | CDC7 | CDC73 | CDCA2 | CDCA3 | CDCA4 | CDCA4P3 | CDCA5 | CDCA7 | CDCA7L | CDCA8 | CDCP1 | CDCP2 | CDH1 | CDH10 | CDH11 | CDH12 | CDH13 | CDH13-AS2 | CDH15 | CDH16 | CDH17 | CDH18 | CDH19 | CDH2 | CDH20 | CDH22 | CDH23 | CDH24 | CDH26 | CDH3 | CDH4 | CDH5 | CDH6 | CDH7 | CDH8 | CDH9 | CDHR1 | CDHR18P | CDHR2 | CDHR3